We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

75 hedge funds and large institutions have $31.1M invested in Galectin Therapeutics in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $19M → $31.1M (+$12.1M)

62% more call options, than puts

Call options by funds: $442K | Put options by funds: $273K

41% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 17

0.84% more ownership

Funds ownership: 16.98% → 17.82% (+0.84%)

3% less funds holding

Funds holding: 77 → 75 (-2)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
75
Holders Change
-2
Holders Change %
-2.6%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
24
Reduced
17
Closed
9
Calls
$442K
Puts
$273K
Net Calls
+$169K
Net Calls Change
+$56K

Top Buyers

Rank Fund Capital Flow
1
CCB
Cutter & Co Brokerage
Missouri
+$465K
2
Osaic Holdings
Osaic Holdings
Arizona
+$373K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$198K
4
Two Sigma Investments
Two Sigma Investments
New York
+$149K
5
N
Nuveen
North Carolina
+$131K

Top Sellers

Rank Fund Capital Flow
1
BWM
BT Wealth Management
Georgia
-$118K
2
BlackRock
BlackRock
New York
-$98.5K
3
Citadel Advisors
Citadel Advisors
Florida
-$91.1K
4
Northern Trust
Northern Trust
Illinois
-$57.1K
5
HS
HighVista Strategies
Massachusetts
-$50K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$36K +$29.7K +11,800 New
AIC
52
Ameritas Investment Company
Nebraska
$33K -$6.29K -2,500 -19%
William Blair & Company
53
William Blair & Company
Illinois
$33K – – –
Bank of America
54
Bank of America
North Carolina
$33K +$16.3K +6,462 +146%
DAS
55
Dynamic Advisor Solutions
Arizona
$31K – – –
TRCT
56
Tower Research Capital (TRC)
New York
$26K +$16.2K +6,423 +300%
Legal & General Group
57
Legal & General Group
United Kingdom
$20K -$850 -338 -5%
SFS
58
Sowell Financial Services
Arkansas
$17K – – –
Citigroup
59
Citigroup
New York
$16K -$17.4K -6,932 -57%
Group One Trading
60
Group One Trading
Illinois
$15K +$164 +65 +1%
GI
61
Gradient Investments
Minnesota
$12K – – –
HPC
62
HM Payson & Co
Maine
$10K – – –
AIP
63
Ameritas Investment Partners
Nebraska
$9K – – –
Bank of Montreal
64
Bank of Montreal
Ontario, Canada
$8K +$7.29K +2,899 +2,899%
Rockefeller Capital Management
65
Rockefeller Capital Management
New York
$6K – – –
BFEC
66
Benjamin F. Edwards & Company
Missouri
$5K – – –
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$4K -$27.2K -10,826 -90%
GRP
68
Global Retirement Partners
California
$4K -$1.13K -450 -26%
PMFA
69
Plante Moran Financial Advisors
Michigan
$4K – – –
BNP Paribas Financial Markets
70
BNP Paribas Financial Markets
France
$3.85K -$28.2K -11,202 -90%
APA
71
American Portfolios Advisors
New York
$3.15K – – –
IA
72
IFP Advisors
Florida
$2K – – –
SIC
73
Salem Investment Counselors
North Carolina
$1K – – –
TWA
74
TCI Wealth Advisors
Arizona
$1K – – –
RE
75
RBC Europe
United Kingdom
$122 – – –
1 2
3
4

GALT Hedge Fund Activity: Q2 2020 in Review

75 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2020, worth a combined $31.1M — up 64% from $19M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of GALT and 8 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 24 added.

The largest buyer was Cutter & Co Brokerage, opening a new position worth an estimated $465K. The largest seller was BT Wealth Management, exiting entirely with an estimated $118K sold.

  • 75 institutional investors held Galectin Therapeutics (GALT) as of Q2 2020, down from 77 in Q1 2020.
  • Funds reported $31.1M of Galectin Therapeutics stock for Q2 2020, up 64% quarter-over-quarter.
  • 8 funds opened new Galectin Therapeutics positions in Q2 2020 and 9 closed out, a net change of -1 holder.
  • The largest Galectin Therapeutics buyer in Q2 2020 was Cutter & Co Brokerage, an estimated $465K added.
  • The largest Galectin Therapeutics seller in Q2 2020 was BT Wealth Management, an estimated $118K sold.

Based on aggregated 13F filings for Q2 2020.